University of Cape Coast Pharmacological

Total Page:16

File Type:pdf, Size:1020Kb

University of Cape Coast Pharmacological © University of Cape Coast https://erl.ucc.edu.gh/jspui UNIVERSITY OF CAPE COAST PHARMACOLOGICAL EVALUATION OF EXTRACT AND ISOLATED COMPOUNDS FROM THE ROOT BARK OF ZIZIPHUS ABYSSINICA HOCHST EX. A RICH (RHAMNACEAE) ISAAC TABIRI HENNEH 2019 Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui ©2019 Isaac Tabiri Henneh University of Cape Coast Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui UNIVERSITY OF CAPE COAST PHARMACOLOGICAL EVALUATION OF EXTRACT AND ISOLATED COMPOUNDS FROM THE ROOT BARK OF ZIZIPHUS ABYSSINICA HOCHST EX. A RICH (RHAMNACEAE) BY ISAAC TABIRI HENNEH Thesis submitted to the Department of Biomedical Sciences of the School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, in partial fulfilment of the requirements for the award of Doctor of Philosophy degree in Drug Discovery and Development SEPTEMBER, 2019 Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui DECLARATION Candidate’s Declaration I hereby declare that this thesis is the result of my own original research and that no part of it has been presented for another degree in this university or elsewhere. Candidate’s Signature:.................................................... Date:........................... Name: Isaac Tabiri Henneh Supervisors’ Declaration We hereby declare that the preparation and presentation of the thesis were supervised in accordance with the guidelines on supervision of thesis laid down by the University of Cape Coast. Principal Supervisor’s Signature:.................................... Date:......................... Name: Prof. Martins Ekor Co-Supervisor’s Signature: ........................................... Date:......................... Name: Dr. Francis Ackah Armah ii Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui ABSTRACT The diversity offered by natural products has timelessly positioned it as a good source for novel therapeutics for the management of various medical conditions, including pain and CNS disorders. This study evaluated hydro- ethanolic root bark extract (ZAE) and isolated compounds from Ziziphus abyssinica for analgesic, anti-inflammatory, anxiolytic and antidepressant properties. Established in vitro and in vivo experimental models were adopted in assessing ZAE and the isolated compounds for these pharmacological properties. Elucidation of structure of the isolated compounds was carried out using infra-red spectroscopy, mass spectrometry, nuclear magnetic resonance and X-ray crystallography. Two pentacyclic triterpenes, β-amyrin and polpunonic acid, were for the first time isolated from the plant. This is also the first time the crystal structure of polpunonic acid is reported. ZAE was found to be relatively safe in acute and sub-chronic toxicity studies in rats. ZAE exhibited analgesic effect that is possibly mediated via opioidergic, ATP- sensitive potassium channels and nitric oxide - cyclic guanosine monophosphate pathways. ZAE also exhibited anti-inflammatory activity via membrane stabilisattion as well as inhibition of protein denaturation, neutrophil degranulation and activity of inflammatory mediators (TNF-α, IL- 1β, prostaglandin E2 and bradykinin). The isolated compounds, β-amyrin and polpunonic acid, also exhibited analgesic, anti-inflammatory (anti-arthritic), anxiolytic and antidepressant properties in murine models. It is concluded that ZAE, β-amyrin and polpunonic acid possess analgesic, anti-inflammatory, anxiolytic and antidepressant properties. iii Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui KEYWORDS β-Amyrin Biological activity Drug discovery Herbal medicine Phytochemistry Polpunonic acid iv Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui ACKNOWLEDGMENTS Doctoral studies is a long expedition which is not possible without the help of God and numerous other people. To this, I say a big thanks to God Almighty for making this dream a reality. I would also like to thank my supervisors Prof. Martins Ekor and Dr. Francis Ackah Armah for their guidance. I acknowledge the support of the Provost, Prof. J. N. Boampong for his encouragement and fatherly role. Also, I appreciate the support given me by the Head of Department, Dr. Desmond Omane Acheampong. My next appreciation goes to Dr. Elvis Ofori Ameyaw, Dr. Robert Peter Biney, Mr. Ernest Obese, Dr. Christian Adokoh, Mr. Dubois Asante and all the lecturers and staff of the Department of Biomedical Sciences and the Department of Pharmacology, University of Cape Coast. I am also very grateful to Prof. Martin Safo and his team at Virginia Commonwealth University, USA, who assisted me with X-ray crystallography analysis of my compounds. I also acknowledge the support of Dr Ben Harley. I would also like to express my gratitude to Emmanuel Adakurugu, Daniels Konja, Eric Otumi, Joseph Acquah-Mills, John Alake, John Afortude, Wisdom Ahliadzi and my colleague students who assisted me in one way or the other in carrying out this work. I cannot end without aknowledging the support of my father, Nana Kwabena Hinneh and my siblings: Mr. T.K. Donkor, Mr. Anthony Asamoah, Lawyer Barima A. Hinneh, Flt. Lt. Dr. Kyere Hinneh, Georgina Ohenewaa and Cecilia Nketia. To my wife, Benedicta Obeng, and my kids: Maame Tabuaa, Obaapa and TK, I say thank you for your love. v Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui DEDICATION This thesis is dedicated to the loving memory of my dear mum: Maame Akua Tabuaa. vi Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui TABLE OF CONTENTS Content Page DECLARATION II ABSTRACT III KEYWORDS IV ACKNOWLEDGMENTS V DEDICATION VI TABLE OF CONTENTS VII LIST OF TABLES XI LIST OF FIGURES XII LIST OF ACRONYMS XXII CHAPTER ONE 1 INTRODUCTION 1 Background to the Study 1 Statement of the Problem and Justification 3 Hypothesis 6 General Objective 6 Significance of the Study 7 Limitation of the Study 8 Definition of terms 9 The Organisation of the Study 10 CHAPTER TWO 12 LITERATURE REVIEW 12 Introduction 12 vii Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui Inflammation 12 Acute and Chronic Inflammation 12 Mediators of Inflammation 14 Rheumatoid Arthritis 17 Models of Inflammation 18 Inflammatory Pain 24 Inflammation and Depression 27 Anxiety 31 Toxicity of Herbal Medicine 34 The Family Rhamnaceae 36 Genus Ziziphus 36 Ziziphus abyssinica 41 CHAPTER THREE 50 MATERIALS AND METHODS 50 Collection of Plant Material 50 Preparation of Plant Extract 50 Phytochemical Tests 50 Biological Activity of the Extract 52 Animals 52 Drugs and Chemicals 52 Toxicity Studies 53 Anti-nociceptive Effect of the Extract 55 Anti-inflammatory Property of the Extract 61 Antidepressant Effect of the Extract 66 Anxiolytic Effect of the Extract 67 Extraction and Isolation of Compounds 68 Biological Activity of the Isolated Compounds 71 viii Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui Analgesic effect of the isolated compounds 75 Antidepressant effect of the isolated compounds 75 Anxiolytic Effect of the isolated compounds 75 Statistical analysis 76 CHAPTER FOUR 77 RESULTS 77 Phytochemical screening 77 Toxicity Studies on the Extract 77 Anti-nociceptive Effect of the Extract 90 Mechanisms of Antinociceptive Action of the Extract 95 Assessment of Involvement of nociceptive Pathways Using the Formalin Test 95 TNF-alpha and Interleukin 1β Induced Hyperalgesia 98 Bradykinin and Prostaglandin E2-induced Hyperalgesia 100 Anti-inflammatory Effect of Extract 102 Antidepressant Effect of the Extract 115 Structural Elucidation of Isolated Compounds 119 Anti-arthritic Effect of the Isolated Compounds 127 Analgesic Effect of the Isolated Compounds 139 Antidepressant Effect of Isolated Compounds 141 Anxiolytic Effect of the Isolated Compounds 144 CHAPTER FIVE 146 DISCUSSION, SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 146 Discussion 146 Summary 169 Conclusions 171 ix Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui Recommendations 172 REFERENCES 173 APPENDICES 199 Appendix A: Spectra Data of Β-Amyrin 199 Appendix B: Spectra Data of Polpunonic Acid 208 Appendix C: Crystal Structure of Polpunonic Acid 218 Appendix D: Results from activity-guided isolation of compounds from the plant. 220 x Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui LIST OF TABLES Table Page 1 List of local names for Ziziphus abyssinica in different parts of the world 42 2 Taxonomy of Ziziphus abyssinica 42 3 Results from phytochemical screening 77 4 The effect of varying doses of ZAE in an acute toxicity study 78 5 13C NMR assignments for compounds 1 and 2 122 6 Crystal data and structure refinement for Compound 2. 123 7 For compound 2 Bond lengths 124 8 Bond Angles for compound 2 125 9 Hydrogen-bond geometry (Å, o) for compound 2 126 xi Digitized by Sam Jonah Library © University of Cape Coast https://erl.ucc.edu.gh/jspui LIST OF FIGURES Figure Page 1 Inflammatory mediators coordinated release initiated by different stimuli. 26 2 Cyclopeptide alkaloids isolated from various species of Ziziphus 37 3 Triterpenoids that have been isolated from various species of Ziziphus 39 4 Flavonoids isolated from various species of Ziziphus 39 5 Ziziphus abyssinica tree, leaves and fruits 43 6 The map above shows countries with the documented
Recommended publications
  • 24Hrs Patent Application Publication May 21 , 2020 Sheet 1 of 6 US 2020/0155522 A1
    US 20200155522A1 IN (19 ) United States (12 ) Patent Application Publication ( 10 ) Pub . No.: US 2020/0155522 A1 Osten et al. (43 ) Pub . Date : May 21 , 2020 (54 ) GABOXADOL FOR REDUCING RISK OF Publication Classification SUICIDE AND RAPID RELIEF OF (51 ) Int. Ci. DEPRESSION A61K 31/437 (2006.01 ) A61K 31/135 (2006.01 ) ( 71) Applicant: Certego Therapeutics , Farmingdale , A61P 25/24 ( 2006.01 ) NY (US ) (52 ) U.S. CI. (72 ) Inventors: Pavel Osten , Brooklyn , NY (US ) ; CPC A61K 31/437 (2013.01 ) ; A61P 25/24 Kristin Baldwin , San Diego , CA (US ) ( 2018.01 ) ; A61K 31/135 ( 2013.01 ) (73 ) Assignee : Certego Therapeutics, Farmingdale , ( 57 ) ABSTRACT NY (US ) Methods and compositions are disclosed for rapidly reduc (21 ) Appl. No.: 16 /691,049 ing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major ( 22 ) Filed : Nov. 21 , 2019 depression and treatment - resistant depression using a novel therapeutic regimen comprising a single or intermittent Related U.S. Application Data administration of a high dose of gaboxadol, or a pharma (60 ) Provisional application No.62 / 770,287 , filed on Nov. ceutically acceptable salt thereof, to the subject n need 21 , 2018 . thereof. 220 I ther 24hrs Patent Application Publication May 21 , 2020 Sheet 1 of 6 US 2020/0155522 A1 FIGURE1:METHODFORWHOLE-BRAINPHARMACOMAPSREPRESENTINGDRUGEVOKED ACTIVATIONINTHEMOUSE. Patent Application Publication May 21 , 2020 Sheet 2 of 6 US 2020/0155522 A1 FIGURE 2 : KETAMINE DOSE - CURVE PHARMACOMAPS , Ketamine
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • The Neurobiology of Treatment-Resistant Depression: from Antidepressant Classifications to Novel Pharmacological Targets
    1521-0081/70/3/475–504$35.00 https://doi.org/10.1124/pr.117.014977 PHARMACOLOGICAL REVIEWS Pharmacol Rev 70:475–504, July 2018 Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets F. Caraci, F. Calabrese, R. Molteni, L. Bartova, M. Dold, G. M. Leggio, C. Fabbri, J. Mendlewicz, G. Racagni, S. Kasper, M. A. Riva,1 and F. Drago1 Departments of Drug Sciences (F.Car.) and Biomedical and Biotechnological Sciences, School of Medicine (G.M.L., F.D.), University of Catania, Catania, Italy; Oasi-Research-Institute-IRCCS, Troina, Italy (F.Car.); Departments of Pharmacological and Biomolecular Sciences (F.Cal., G.R., M.A.R.) and Medical Biotechnology and Translational Medicine (R.M.), Università degli Studi di Milano, Milan, Italy; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (L.B., M.D., S.K.); Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (C.F.); and School of Medicine, Universite’ Libre de Bruxelles, Bruxelles, Belgium (J.M.) Abstract ...................................................................................476 I. Introduction . ..............................................................................476 Downloaded from II. The New Neuroscience-Based Nomenclature and the Classification of Antidepressant
    [Show full text]
  • Bipolar Depression: a Major Unsolved Challenge Ross J
    Baldessarini et al. Int J Bipolar Disord (2020) 8:1 https://doi.org/10.1186/s40345-019-0160-1 REVIEW Open Access Bipolar depression: a major unsolved challenge Ross J. Baldessarini1,2* , Gustavo H. Vázquez2,3 and Leonardo Tondo1,2,4 Abstract Depression in bipolar disorder (BD) patients presents major clinical challenges. As the predominant psychopathol- ogy even in treated BD, depression is associated not only with excess morbidity, but also mortality from co-occurring general-medical disorders and high suicide risk. In BD, risks for medical disorders including diabetes or metabolic syndrome, and cardiovascular disorders, and associated mortality rates are several-times above those for the general population or with other psychiatric disorders. The SMR for suicide with BD reaches 20-times above general-popula- tion rates, and exceeds rates with other major psychiatric disorders. In BD, suicide is strongly associated with mixed (agitated-dysphoric) and depressive phases, time depressed, and hospitalization. Lithium may reduce suicide risk in BD; clozapine and ketamine require further testing. Treatment of bipolar depression is far less well investigated than unipolar depression, particularly for long-term prophylaxis. Short-term efcacy of antidepressants for bipolar depres- sion remains controversial and they risk clinical worsening, especially in mixed states and with rapid-cycling. Evidence of efcacy of lithium and anticonvulsants for bipolar depression is very limited; lamotrigine has long-term beneft, but valproate and carbamazepine are inadequately tested and carry high teratogenic risks. Evidence is emerging of short-term efcacy of several modern antipsychotics (including cariprazine, lurasidone, olanzapine-fuoxetine, and quetiapine) for bipolar depression, including with mixed features, though they risk adverse metabolic and neurologi- cal efects.
    [Show full text]
  • New Drug Update 2019: a Formulary Approach
    AAIP 8/13/2020 .I have no relationships with commercial interests related to the content of this presentation. J. Russell May, Pharm.D., FASHP Clinical Professor University of Georgia College of Pharmacy ® After attending the presentation and discussion, the .Lefamulin (Xenleta ) by Nabriva Therapeutics attendee should be able to: .Cefiderocol (Fetroja ®) by Shiongi .Bremelanotide (Vyleesi®) by Amag Compare and contrast newly approved drugs with older agents ® regarding their pharmacology, pharmacokinetics, efficacy, safety, .Lasmiditan (Reyvow ) by Lilly dosage and cost. .Ubrogepant (Ubrelvy ®) by Allergan Apply the “formulary approach” to evaluating new drugs. .Eptinezumab-jjmr (Vyepti ®) by Lundbeck Identify other recently approved medications and discuss their ® indications and potential usefulness .Crizanlizumab-tmca (Adakveo ) by Novartis Discuss any pipeline drugs that may be significant releases in the .Voxelotor (Oxbryta ®) by Global Blood therapeutics next few years. .Solriamfetol (Sunosi®) by Jazz . A finite list of therapeutic agents For a drug to be recommended for addition to our . Established value in light of current medical Formulary, it must meet at least one of the following: opinion . New Pharmacological Class . Sufficiently broad to meet the usual clinical . More Efficacious problems . Safer . Avoids duplication of clinical effect . Pharmacokinetic Advantage (clinically relevant) . Subject to continuing revision based on new . More Cost Effective therapeutic knowledge 1 AAIP 8/13/2020 Lefamulin (Xenleta®) Pharmacology
    [Show full text]
  • Orally Active Compound Library (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
    [Show full text]
  • JN1540 Depression Whitepaper 3.Indd
    Depression: New Insights Shifting the Treatment Paradigm 2 / October 2018 © Informa UK Ltd 2018 (Unauthorized photocopying prohibited.) Philippa Nutkins Drug Analyst, Citeline Breathing Life into a Stagnant Pipeline It is clear that we are in the middle of an epidemic Selective serotonin reuptake inhibitors (SSRIs), such of mood disorders, with depression alone affecting as Prozac (fluoxetine; Eli Lilly) and Celexa (citalopram approximately 1 in 6 adults in the US.1 The complex hydrobromide; Allergan), remain first-line therapies pathology of depression is not understood, and the in the US and EU markets2. However, with an condition often becomes a lifelong chronic disorder, estimated 10–30% of depression patients becoming creating enormous sociological and clinical burdens. treatment-resistant, high unmet need presents a dilemma for healthcare providers. Depression is a complex phenomenon, with several contributing pathways and a multitude of The development of novel classes of antidepressants symptoms which may or may not be present. In – such as those targeting the NMDA and opioid addition to the unclear aetiology, the translatability receptor pathways – provides hope that future of animal models is lacking in depression, and breakthroughs are on the horizon. This analysis, clinical trials, even of proven antidepressants, are using Pharmaprojects and Trialtrove intelligence, prone to missing their primary endpoints. Such explores the current R&D landscape with an eye factors are contributing to the exit of Big Pharma out towards highlighting novel treatment paradigms of depression, with GlaxoSmithKline, AstraZeneca and assessing where the market might be heading. and Pfizer being high-profile examples. 1. US Department of Health and Human Services (2014) Results from the 2013 National Survey on Drug Use and Health: Mental Health Findings.
    [Show full text]
  • Onset Antidepressant Effect? a Concise Overview of the Surprisingly Large Number of Possibilities
    Journal of Clinical Pharmacy and Therapeutics, 2017, 42,147–154 doi: 10.1111/jcpt.12497 Review Article What is the mechanism of Ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities S. E. Strasburger* PharmD, P. M. Bhimani* PharmD, J. H. Kaabe* PharmD, J. T. Krysiak* PharmD, D. L. Nanchanatt* PharmD, T. N. Nguyen* PharmD, K. A. Pough* PharmD, T. A. Prince* PharmD, N. S. Ramsey* PharmD, K. H. Savsani* PharmD, L. Scandlen* PharmD, M. J. Cavaretta* PharmD and R. B. Raffa*† PhD *Temple University School of Pharmacy, Philadelphia, PA, and †University of Arizona College of Pharmacy, Tucson, AZ, USA Received 29 October 2016, Accepted 29 November 2016 Keywords: ketamine, major depressive disorder, mechanism of action, NMDA receptor, rapid-onset antidepressant for the understanding and treatment of depressive illness. There SUMMARY is some convergence on NMDA receptor antagonism as a likely, What is known and objective: Abundant clinical data now but to date unproven, common mechanism. The surprising confirm that ketamine produces a remarkable rapid-onset number of other mechanisms, and the several novel biochemical antidepressant effect – hours or days – in contrast to the delayed aetiologies of depression proposed, suggests exciting new drug- onset (typically weeks) of current antidepressant drugs. This discovery targets. surprising and revolutionary finding may lead to the develop- ment of life-saving pharmacotherapy for depressive illness by reducing the high suicide risk associated with the delayed onset WHAT IS KNOWN AND OBJECTIVE of effect of current drugs. As ketamine has serious self-limiting The diagnostic criteria for major depressive disorder (MDD) as drawbacks that restrict its widespread use for this purpose, a delineated in the Diagnostic and Statistical Manual of Mental safer alternative is needed.
    [Show full text]
  • Membrane Transporter/Ion Channel
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Membrane Transporter/Ion Channel Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, binding with small molecules in extracellular space, the recognition process in the immune system, energy transduction, osmoregulation, and physiological and developmental processes. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. ATP-powered pumps are ATPases that use the energy of ATP hydrolysis to move ions or small molecules across a membrane against a chemical concentration gradient or electric potential. Channel proteins transport water or specific types of ions down their concentration or electric potential gradients. Many other types of channel proteins are usually closed, and open only in response to specific signals. Because these types of ion channels play a fundamental role in the functioning of nerve cells. Transporters, a third class of membrane transport proteins, move a wide variety of ions and molecules across cell membranes. Membrane transporters either enhance or restrict drug distribution to the target organs. Depending on their main function, these membrane transporters are divided into two categories: the efflux (export) and the influx (uptake) transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system ion channels have been linked to many diseases such, but not limited to, ataxias, paralyses, epilepsies, and deafness indicative of the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information.
    [Show full text]
  • Focus on Rapid Antidepressant Treatments Cristina Cusin, MD Depression Clinical and Research Program Assistant Professor HMS
    Rapid Treatments for Psychiatric Disorders: focus on rapid antidepressant treatments Cristina Cusin, MD Depression Clinical and Research Program Assistant Professor HMS www.mghcme.org Disclosures Cristina Cusin 2012-2017: – Speaking/CME/Consulting: Janssen, Takeda, Boehringer – Equity: None – Royalty/patent: PCT/US15/56192; 070919.00032 Acyliccucurbit[N]uril type molecular containers to treat intoxication and substance abuse www.mghcme.org Definition of rapid? • What does it mean “rapid”? • “Rapid” compared to what? • How do we compare with other specialties? (cardiology, anesthesia, neurology - stroke, pain, infectious disease) • If you had acute pain from kidney stone and the only ‘effective’ treatment was a drug with a chance of improvement of 45% in 6 weeks how would you feel? www.mghcme.org “Rapid treatments” at MGH in 1976 Rapid treatment of acute psychosis • 24 patients with acute functional psychoses (schizophrenia or mania) were treated with IM haloperidol in a three-hour period. • 5mg -> +10 mg Q30min vs 5mg-> +5mgQhr • There was almost complete remission of cardinal symptoms (thought disorder, hallucinations, and delusional activity) in this period for 11 patients. “Acute dystonia, easily reversed, was the only significant side effect” Anderson WH, American Journal Psychiatry, 1976, 133 (9) 1076-1078 www.mghcme.org Rapid for what problem? (Hint: Think emergency room setting) • Violent behavior • Psychosis • Intoxication/Overdose • Withdrawal • Drug reaction or interaction • Anxiety/Panic • Depression /Suicidality www.mghcme.org
    [Show full text]
  • Novel Treatments for Mood Disorders
    Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts General Hospital www.mghcme.org Disclosures My spouse/partner and I have the following relevant financial relationship with a commercial interest to disclose: Spouse is an employee of Roche Pharmaceuticals www.mghcme.org MDD Statistics • 12 month prevalence U.S.: 9% • Mortality from Suicide: 20+ x gen pop • Increased risk of CV death. • Economic Costs to U.S: $36.6 Billion Lepine JP, Briley M. Neuropsychiatr Dis Treat 2011; 7(suppl 1) 3-7. www.mghcme.org Network Depression Model: must accommodate defining clinical symptoms attention-cognition-action PF9 PM6 P40 pCg hippocampus mF9/10 self emotion- mood cognition aCg24 salience cd-vs thal mb-sn state integration oF11 reward Cg25 a-ins am hth pag/dr arousal-autonomic-circadian www.mghcme.org Depression Model Adapted from Mayberg, 2003 www.mghcme.org Potential Mechanisms For New Antidepressant Treatments Monoamines Augmentation Opioids Glutamate/GABA Inflammation /Metabolic Neuromodulation www.mghcme.org Monoamine Projections Neurowiki2012 –MAO in depression www.mghcme.org Serotonin Modulators • FKB01 MD - SSRI (TCA’s) - 5-HT2; 5-HT1A agonist; 5-HT1D - Speed of onset may be faster. • Lumateperone ITI-007 - Bipolar Depression; Schizophrenia; Dementia - SSRI; 5-HT2A, D2 antagonist; presynaptic D2 partial agonist. - Negative symptoms. - Phase III • Min-117 - SDRI - Targets “Anxio-Depressive symptoms”. www.mghcme.org Triple Reuptake Inhibitors (SNDRI’s) • Ideal Profile: Strong SERT; intermediate NET; and mild DAT inhibition. S. Stahl 2013 • Cocaine • Phencyclidine • Ketamine • Ginkgo biloba extract (EGb761) Wikipedia 2017 www.mghcme.org SNDRI’s • Amitifadine: -SERT:NET:DAT:12:23:96 -Positive - phase IIa trial -Negative - phase IIb/IIIa trial - ? Dosing -Weight loss development program • Ansofaxine -Prodrug of desvenlafaxine -SERT:NET:DAT: 4:5:3 -Phase I trials completed.
    [Show full text]
  • Professor Siegfried Kasper Chair
    Professor Siegfried Kasper Chair Department of Psychiatry and Psychotherapy Medical University of Vienna (MUW) 1 Potential Conflicts of Interest (January 2015 to present) Dr Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for AOP Orphan Pharmaceuticals AG, Eli Lilly, Janssen, Lundbeck, Schwabe and Takeda; and he has served on speakers bureaus for Angelini, AOP Orphan Pharmaceuticals AG, Eli Lilly, Krka Pharma, Lundbeck, Neuraxpharma, Pierre Fabre, Schwabe, Servier, Sun Pharma. Siegfried KASPER Department of Psychiatry and Psychotherapy 2 Siegfried KASPER Department of Psychiatry and Psychotherapy 4 Siegfried KASPER Department of Psychiatry and Psychotherapy 6 Neuropharmacology of NMDA Receptor Antagonist Ketamine ▪hypnotic ▪amnesic ▪analgesic ▪psychotomimetic R(-) ketamine S(+) ketamine: 3-4 times higher affinity Siegfried KASPER Department of Psychiatry and Psychotherapy 7 Major depression is a disorder of synaptic plasticity Chronic unpredictable stress induces a depression-like phenotype in rodents which is associated with reversible decreases in the branching complexity1 and spine density2,3 of pyramidal neurons in the prefrontal cortex Control Control Stressed Treated Stressed Stress- Tx- induced induced spine spine loss formation 1. Duman RS, Aghajanuan GK. Science. 2012;338(6103)68-72); 2. Li N, et al. Biol Psychiatry. 2011;69(8):754–761; 3. Nestler EJ et al. Neuron. 2002;34:13-25. Siegfried KASPER Department of Psychiatry and Psychotherapy 8 Depression: Glutamate-GABA
    [Show full text]